Sanofi, Regeneron bag EC approval for skin cancer drug Libtayo

This article was originally published here

The European approval for Libtayo is for such patients who are not eligible for curative surgery or curative radiation. The skin cancer drug was given the regulatory nod

The post Sanofi, Regeneron bag EC approval for skin cancer drug Libtayo appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply